172 related articles for article (PubMed ID: 17310821)
1. Virological response and incidence of adefovir resistance in lamivudine-resistant patients treated with adefovir dipivoxil.
Chen CH; Wang JH; Lee CM; Hung CH; Hu TH; Wang JC; Lu SN; Changchien CS
Antivir Ther; 2006; 11(6):771-8. PubMed ID: 17310821
[TBL] [Abstract][Full Text] [Related]
2. Detection of rtN236T and rtA181V/T mutations associated with resistance to adefovir dipivoxil in samples from patients with chronic hepatitis B virus infection by the INNO-LiPA HBV DR line probe assay (version 2).
Osiowy C; Villeneuve JP; Heathcote EJ; Giles E; Borlang J
J Clin Microbiol; 2006 Jun; 44(6):1994-7. PubMed ID: 16757589
[TBL] [Abstract][Full Text] [Related]
3. Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil.
Yeon JE; Yoo W; Hong SP; Chang YJ; Yu SK; Kim JH; Seo YS; Chung HJ; Moon MS; Kim SO; Byun KS; Lee CH
Gut; 2006 Oct; 55(10):1488-95. PubMed ID: 16461777
[TBL] [Abstract][Full Text] [Related]
4. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir.
Lada O; Benhamou Y; Cahour A; Katlama C; Poynard T; Thibault V
Antivir Ther; 2004 Jun; 9(3):353-63. PubMed ID: 15259898
[TBL] [Abstract][Full Text] [Related]
5. Overlap lamivudine treatment in patients with chronic hepatitis B receiving adefovir for lamivudine-resistant viral mutants.
Liu CJ; Kao JH; Chen PJ; Chen TC; Lin FY; Lai MY; Chen DS
J Viral Hepat; 2006 Jun; 13(6):387-95. PubMed ID: 16842441
[TBL] [Abstract][Full Text] [Related]
6. Virologic response and resistance to adefovir in patients with chronic hepatitis B.
Fung SK; Chae HB; Fontana RJ; Conjeevaram H; Marrero J; Oberhelman K; Hussain M; Lok AS
J Hepatol; 2006 Feb; 44(2):283-90. PubMed ID: 16338024
[TBL] [Abstract][Full Text] [Related]
7. Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir.
Brunelle MN; Jacquard AC; Pichoud C; Durantel D; Carrouée-Durantel S; Villeneuve JP; Trépo C; Zoulim F
Hepatology; 2005 Jun; 41(6):1391-8. PubMed ID: 15915463
[TBL] [Abstract][Full Text] [Related]
8. Viral kinetics in patients with lamivudine-resistant hepatitis B during adefovir-lamivudine combination therapy.
Mihm U; Gärtner BC; Faust D; Hofmann WP; Sarrazin C; Zeuzem S; Herrmann E
J Hepatol; 2005 Aug; 43(2):217-24. PubMed ID: 15964093
[TBL] [Abstract][Full Text] [Related]
9. Switching to adefovir monotherapy after emergence of lamivudine-resistant mutations in patients with liver cirrhosis.
Liaw YF; Lee CM; Chien RN; Yeh CT
J Viral Hepat; 2006 Apr; 13(4):250-5. PubMed ID: 16611191
[TBL] [Abstract][Full Text] [Related]
10. Changes in viral loads of lamivudine-resistant mutants and evolution of HBV sequences during adefovir dipivoxil therapy.
Suzuki F; Kumada H; Nakamura H
J Med Virol; 2006 Aug; 78(8):1025-34. PubMed ID: 16789011
[TBL] [Abstract][Full Text] [Related]
11. Severe exacerbation of chronic hepatitis B after emergence of lamivudine resistance in a cirrhotic patient: immediate switch to adefovir dipivoxil appears to be indicated.
Wiegand J; Tischendorf JJ; Nashan B; Klempnauer J; Flemming P; Niemann P; Rohde P; Manns MP; Trautwein C; Tillmann HL
Z Gastroenterol; 2004 Jan; 42(1):15-8. PubMed ID: 14997399
[TBL] [Abstract][Full Text] [Related]
12. Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy.
van Bömmel F; Zöllner B; Sarrazin C; Spengler U; Hüppe D; Möller B; Feucht HH; Wiedenmann B; Berg T
Hepatology; 2006 Aug; 44(2):318-25. PubMed ID: 16871563
[TBL] [Abstract][Full Text] [Related]
13. Clinical and virological response to adefovir dipovixil for lamivudine-resistant HBeAg-negative hepatitis B.
Scotto G; Palumbo E; Fazio V; Tartaglia A; Saracino A; Angarano G
New Microbiol; 2005 Jul; 28(3):193-7. PubMed ID: 16240690
[TBL] [Abstract][Full Text] [Related]
14. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants.
Zhang WX; Lai V; Mutimer D; Mirza D
Hepatobiliary Pancreat Dis Int; 2006 Feb; 5(1):154-6. PubMed ID: 16481305
[TBL] [Abstract][Full Text] [Related]
15. Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine.
Lampertico P; Viganò M; Manenti E; Iavarone M; Lunghi G; Colombo M
Hepatology; 2005 Dec; 42(6):1414-9. PubMed ID: 16317671
[TBL] [Abstract][Full Text] [Related]
16. Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks.
Yang H; Westland CE; Delaney WE; Heathcote EJ; Ho V; Fry J; Brosgart C; Gibbs CS; Miller MD; Xiong S
Hepatology; 2002 Aug; 36(2):464-73. PubMed ID: 12143057
[TBL] [Abstract][Full Text] [Related]
17. Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy.
Lee YS; Suh DJ; Lim YS; Jung SW; Kim KM; Lee HC; Chung YH; Lee YS; Yoo W; Kim SO
Hepatology; 2006 Jun; 43(6):1385-91. PubMed ID: 16729316
[TBL] [Abstract][Full Text] [Related]
18. [Resistance to adefovir in patients with chronic hepatitis B].
Ryu SH; Chung YH
Korean J Hepatol; 2006 Dec; 12(4):484-92. PubMed ID: 17237626
[TBL] [Abstract][Full Text] [Related]
19. Prophylaxis of hepatitis B virus recurrence after liver transplantation in carriers of lamivudine-resistant mutants.
Marzano A; Lampertico P; Mazzaferro V; Carenzi S; Vigano M; Romito R; Pulvirenti A; Franchello A; Colombo M; Salizzoni M; Rizzetto M
Liver Transpl; 2005 May; 11(5):532-8. PubMed ID: 15838891
[TBL] [Abstract][Full Text] [Related]
20. Variant of hepatitis B virus with primary resistance to adefovir.
Schildgen O; Sirma H; Funk A; Olotu C; Wend UC; Hartmann H; Helm M; Rockstroh JK; Willems WR; Will H; Gerlich WH
N Engl J Med; 2006 Apr; 354(17):1807-12. PubMed ID: 16641397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
